Gut dysbiosis in oncology: a risk factor for immunoresistance - Cell Research

Nature·Jan 14

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Research suggests that gut dysbiosis may be a risk factor for immunoresistance in oncology. Studies are exploring the relationship between the gut microbiome and various health conditions, including cancer, sepsis, and kidney disease. The gut microbiome's composition and its impact on treatment outcomes and overall health are being investigated in different contexts, including cancer treatment and patient care.

Full coverage

Host–microbiome interactions in breast cancer progression and treatment response

Frontiers·May 13

GMFH World Summit 2026: Diet and other ways to manipulate the gut microbiome in clinical practice

Gut Microbiota for Health·May 14

Intestinal dysbiosis as an intraoperative predictor of septic complications: evidence from human surgical cohorts and preclinical models of peritoneal sepsis

Nature·Dec 21

Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia | Scientific Reports

Nature·Apr 15

Characteristics of the gut mycobiome in patients with membranous nephropathy

Nature·Feb 20

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling

Nature·Jun 25

Study on intestinal parasitic infections and gut microbiota in cancer patients at a tertiary teaching hospital in Malaysia

Nature·Jun 13

Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients

Nature·Sep 11

View original report at Nature ↗

Fetching the latest headlines…